CY1463A - A new crystal modification of cimetidine and process for preparing and using same - Google Patents
A new crystal modification of cimetidine and process for preparing and using same Download PDFInfo
- Publication number
- CY1463A CY1463A CY1463A CY146389A CY1463A CY 1463 A CY1463 A CY 1463A CY 1463 A CY1463 A CY 1463A CY 146389 A CY146389 A CY 146389A CY 1463 A CY1463 A CY 1463A
- Authority
- CY
- Cyprus
- Prior art keywords
- methyl
- ethyl
- cyanoguanidine
- methylimidazol
- methylthio
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims description 27
- 238000012986 modification Methods 0.000 title claims description 27
- 230000004048 modification Effects 0.000 title claims description 27
- 229960001380 cimetidine Drugs 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- -1 5-methylimidazol-4-yl Chemical group 0.000 claims description 26
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000010586 diagram Methods 0.000 claims description 5
- 238000010899 nucleation Methods 0.000 claims description 3
- 238000002329 infrared spectrum Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 11
- 238000001816 cooling Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- APQPRKLAWCIJEK-UHFFFAOYSA-N cystamine Chemical compound NCCSSCCN APQPRKLAWCIJEK-UHFFFAOYSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229940097265 cysteamine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- SPVRWVNZBKXMQW-UHFFFAOYSA-N ethyl acetate;propan-2-one;hydrate Chemical compound O.CC(C)=O.CCOC(C)=O SPVRWVNZBKXMQW-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- MHGGQXIPBPGZFB-UHFFFAOYSA-N methyl n-cyano-n'-methylcarbamimidothioate Chemical compound CSC(=NC)NC#N MHGGQXIPBPGZFB-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU812767A HU185457B (en) | 1981-09-25 | 1981-09-25 | Process for preparating cimetidine-z |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1463A true CY1463A (en) | 1989-07-21 |
Family
ID=10961014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY1463A CY1463A (en) | 1981-09-25 | 1989-07-21 | A new crystal modification of cimetidine and process for preparing and using same |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4537900A (en, 2012) |
| JP (1) | JPS5867676A (en, 2012) |
| AT (1) | AT378187B (en, 2012) |
| BE (1) | BE894464A (en, 2012) |
| CY (1) | CY1463A (en, 2012) |
| DE (1) | DE3235459A1 (en, 2012) |
| FR (1) | FR2513636B1 (en, 2012) |
| GB (1) | GB2108117B (en, 2012) |
| HU (1) | HU185457B (en, 2012) |
| NL (1) | NL189461C (en, 2012) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA868957B (en) * | 1985-12-06 | 1987-07-29 | Yamanouchi Pharma Co Ltd | Crystals of nalpha-(((s)-4-oxo-2-azetidinyl)carbonyl)-l-histidyl-l-prolinamide and process for producing the crystals |
| FR2593065B1 (fr) * | 1986-01-22 | 1988-09-09 | Smith Kline French Lab | Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation. |
| GB8618846D0 (en) * | 1986-08-01 | 1986-09-10 | Smithkline Beckman Corp | Chemical process |
| GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
| HU196775B (en) * | 1986-08-05 | 1989-01-30 | Richter Gedeon Vegyeszet | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
| JPH064601B2 (ja) * | 1987-11-04 | 1994-01-19 | 三井石油化学工業株式会社 | Ｎ−シアノ−ｎ’−メチル−ｎ’’−［２−｛（５−メチル−１ｈ−イミダゾール−４−イル）メチルチオ｝エチルグアニジンの精製法 |
| US5808090A (en) * | 1996-02-22 | 1998-09-15 | Endo Pharmaceuticals Inc. | Process for preventing precipitation in cimetidine injection solutions |
| US20040265440A1 (en) * | 2002-09-16 | 2004-12-30 | Agcert International, Llc | Food borne pathogen sensor and method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ184893A (en) * | 1976-09-21 | 1980-11-28 | Smith Kline French Lab | Pure crystalline form of cimetidine a(n-methyl-n-cyano-n-(-2-(5-methyl-4imidazolyl) methylthio) ethyl)-guanidine andpharmaceutical compositions containing it |
| JPS56104868A (en) * | 1980-01-24 | 1981-08-20 | Fujimoto Seiyaku Kk | Conversion between polymorphous crystals of cimetidine |
-
1981
- 1981-09-25 HU HU812767A patent/HU185457B/hu not_active IP Right Cessation
-
1982
- 1982-09-22 AT AT0352282A patent/AT378187B/de not_active IP Right Cessation
- 1982-09-22 BE BE1/10593A patent/BE894464A/fr not_active IP Right Cessation
- 1982-09-23 GB GB08227164A patent/GB2108117B/en not_active Expired
- 1982-09-23 NL NLAANVRAGE8203688,A patent/NL189461C/xx not_active IP Right Cessation
- 1982-09-24 JP JP57166411A patent/JPS5867676A/ja active Granted
- 1982-09-24 DE DE3235459A patent/DE3235459A1/de active Granted
- 1982-09-24 FR FR8216090A patent/FR2513636B1/fr not_active Expired
-
1984
- 1984-07-20 US US06/632,311 patent/US4537900A/en not_active Expired - Fee Related
-
1989
- 1989-07-21 CY CY1463A patent/CY1463A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0357895B2 (en, 2012) | 1991-09-03 |
| US4537900A (en) | 1985-08-27 |
| AT378187B (de) | 1985-06-25 |
| DE3235459C2 (en, 2012) | 1991-11-28 |
| ATA352282A (de) | 1984-11-15 |
| GB2108117A (en) | 1983-05-11 |
| FR2513636A1 (fr) | 1983-04-01 |
| DE3235459A1 (de) | 1983-04-14 |
| JPS5867676A (ja) | 1983-04-22 |
| HU185457B (en) | 1985-02-28 |
| NL8203688A (nl) | 1983-04-18 |
| NL189461B (nl) | 1992-11-16 |
| GB2108117B (en) | 1985-10-30 |
| BE894464A (fr) | 1983-03-22 |
| NL189461C (nl) | 1993-04-16 |
| FR2513636B1 (fr) | 1986-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0149172B1 (ko) | 치환 이소플라본 유도체의 개량된 제조방법 | |
| WO1997024358A1 (en) | Process for preparation of cefdinir | |
| US4537900A (en) | Cimetidine Z, a new crystal modification of cimetidine | |
| SI21236A (sl) | Postopek kristalizacije losartan kalija | |
| KR920002295B1 (ko) | 프롤리디논 유도체의 제조방법 | |
| FI79301C (fi) | Foerfarande foer framstaellning av 4-metyl-5- alkyltiometylimidazoler. | |
| JPH04279565A (ja) | ４−クロロ−３−スルファモイル−ｎ−（２，３−ジヒドロ−２−メチル−１ｈ−インドール−１−イル）ベンズアミドの新規な工業的製造方法 | |
| FI90419B (fi) | Menetelmä 1- 2-/5-dimetyyliaminometyyli-2-(furyylimetyylitio)etyyli/ amino-1-metyyliamino-2-nitroeteenin ja sen hydrokloridin valmistamiseksi | |
| SU694071A3 (ru) | Способ получени производных пиперазина или их кислых аддитивных солей или четвертичных солей | |
| JPH0153272B2 (en, 2012) | ||
| GB2041932A (en) | Method for producing 6,7-dimethoxy-4-amino-2-(4-(2-furoyl)-1-piper-azinyl) quinazoline hydrochloride | |
| AU2004203941B2 (en) | Process for preparing substituted imidazole derivatives and intermediates used in the process | |
| US4579954A (en) | Cimetidine monohydrate | |
| HU196386B (en) | Process for production of derivatives of substituated ethan-diimid-amid | |
| HUP0600347A2 (en) | Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon) and the intermediate | |
| EP0500952A1 (en) | Process for producing nitrogenous heterocycle | |
| RU2042671C1 (ru) | Производное дикетен-имина в качестве промежуточного продукта для синтеза ранитидина и способ его получения | |
| JPS636063B2 (en, 2012) | ||
| RU2032681C1 (ru) | Способ получения 1-(2-[(5-диметиламинометил-2-фурил) -метилтио]-этил)-амино-1- метиламино-2-нитроэтилена | |
| GB2103206A (en) | Process for preparing an imidazole derivative | |
| HU193497B (en) | Process for preparing sanitidine hydrogen halogenides | |
| CS248717B2 (en) | Production method of the hydrochloride of the 1-(2-(5 dimethylamino-methyl-2-furylmethylthio)ethyl)p)amino-1-methylamino-2-nitroethylene | |
| BG61303B1 (bg) | метод за получаване на n-(3-(3-(1-пиперидинилметил)фенокси) пропил)ацетоксиацетамид хидрохлорид | |
| JPH0782242A (ja) | Ｎ−置換−１−メチルチオ−２−ニトロエテンアミン類の単離方法 | |
| JPH0135820B2 (en, 2012) |